虚拟现实与Kalinox®在心脏术后ICU疼痛管理中的随机研究
该前瞻性、非劣效性、开放标签随机研究纳入200例心脏术后拔除胸管患者,随机接受Kalinox®(N2O与O2等摩尔混合气体吸入)或虚拟现实(VR)干预,以镇痛/伤害性刺激指数(ANI)变化为主要终点,预设非劣效界值为3分。结果显示Kalinox®组ΔANI为-15.1 ± 12.9,VR组为-15.7 ± 11.6,组间平均差异-0.6 [-3.6至2.4],未达到预设的非劣效性统计要求。VR组拔管后即刻疼痛NRS显著更高(5.0 [3.0-7.0] vs 3.0 [2.0-6.0],p=0.009),但10分钟后无差异;两组焦虑NRS无差异。作者认为VR在ICU疼痛焦虑整体管理中可能的作用仍需更多研究确定。
要点
- 心脏术后拔除胸管时,VR组ΔANI为-15.7 ± 11.6,Kalinox®组为-15.1 ± 12.9,组间平均差异-0.6 [-3.6至2.4],未达到预设的3分非劣效界值。
- VR组拔管后即刻疼痛NRS为5.0 [3.0-7.0],显著高于Kalinox®组的3.0 [2.0-6.0],p=0.009。
- 拔管后10分钟两组疼痛NRS无差异,焦虑NRS在两组间亦无差异。
- 该研究为前瞻性、非劣效性、开放标签随机研究,共纳入200例患者(VR组99例,Kalinox®组101例),符合方案分析每组各90例。
- 作者结论:基于ANI,VR未达到优于Kalinox®的统计学非劣效要求,且基于NRS疼痛评分VR效果较差;VR在ICU疼痛焦虑管理中的可能地位仍需更多研究确定。
适用人群与场景
- 心脏术后在ICU拔除胸管的患者,中位年龄68.0岁 [60.0-74.8]。
诊断标准与关键阈值
- 以镇痛/伤害性刺激指数(ANI)评估疼痛与焦虑,主要终点为操作期间ΔANI(ANImin - ANI0),基于ANIm(4分钟平均值)。
- 预设VR相对于Kalinox®的非劣效界值为3分。
处置流程与药物剂量
- Kalinox®组:拔除胸管期间吸入N2O与O2等摩尔混合气体(Kalinox®)。
- VR组:拔除胸管期间进行虚拟现实(VR)干预。
- 操作期间监测镇痛/伤害性刺激指数(ANI)用于客观评估疼痛和焦虑。
- 采用数字评分量表(NRS)评估患者自报疼痛和焦虑。
研究设计与关键结果
- 研究类型:前瞻性、非劣效性、开放标签随机研究;纳入200例患者,VR组99例,Kalinox®组101例;符合方案分析每组各90例;中位年龄68.0岁 [60.0-74.8]。
- 主要终点ΔANI:Kalinox®组-15.1 ± 12.9 vs VR组-15.7 ± 11.6(NS);组间平均差异-0.6 [-3.6至2.4],包含非劣效界值3分。
- 拔除胸管后即刻疼痛NRS:VR组5.0 [3.0-7.0] vs Kalinox®组3.0 [2.0-6.0],p=0.009,VR组显著更高。
- 拔除胸管后10分钟疼痛NRS:两组无差异。
- 焦虑NRS:两组间无差异。
证据类型、等级与局限
- 证据类型:前瞻性、非劣效性、开放标签随机研究。
- 作者结论:基于ANI,VR在拔除胸管期间管理疼痛和焦虑方面未达到优于Kalinox®的统计学非劣效要求;基于NRS,VR效果较差。
- 作者指出:需要更多研究来确定VR在ICU疼痛和焦虑整体管理中是否可能有一席之地。
- 局限:原文未报告局限性。
对床旁实践的改变
- 基于ANI,VR在心脏术后拔除胸管时的镇痛抗焦虑效果未达到非劣效于Kalinox®的统计学要求,且拔管后即刻自报疼痛NRS更高(5.0 [3.0-7.0] vs 3.0 [2.0-6.0],p=0.009)。
- 作者认为,VR在ICU疼痛和焦虑整体管理中是否可能有一席之地仍需更多研究确定。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: The management of pain and anxiety remains a challenge in the intensive care unit. By distracting patients, virtual reality (VR) may have a role in painful procedures. We compared VR vs. an inhaled equimolar mixture of N2O and O2 (Kalinox®) for pain and anxiety management during the removal of chest drains after cardiac surgery.
METHODS: Prospective, non-inferiority, open-label study. Patients were randomized, for Kalinox® or VR session during drain removal. The analgesia/nociception index (ANI) was monitored during the procedure for objective assessment of pain and anxiety. The primary endpoint was the ΔANI (ANImin - ANI0) during the procedure, based on ANIm (average on 4 min). We prespecified VR as non-inferior to Kalinox® with a margin of 3 points. Self-reported pain and anxiety were also analysed using numeric rate scale (NRS).
RESULTS: 200 patients were included, 99 in the VR group and 101 in the Kalinox® group; 90 patients were analysed in both groups in per-protocol analysis. The median age was 68.0 years [60.0-74.8]. The ΔANI was - 15.1 ± 12.9 in the Kalinox® group and - 15.7 ± 11.6 in the VR group (NS). The mean difference was, therefore, - 0.6 [- 3.6 to 2.4], including the non-inferiority margin of 3. Patients in the VR group had a significantly higher pain NRS scale immediately after the drain removal, 5.0 [3.0-7.0] vs. 3.0 [2.0-6.0], p = 0.009, but no difference 10 min after. NRS of anxiety did not differ between the two groups.
CONCLUSION: Based on the ANI, the current study showed that VR did not reach the statistical requirements for a proven non-inferiority vs. Kalinox® in managing pain and anxiety during chest drain removal. Moreover, VR was less effective based on NRS. More studies are needed to determine if VR might have a place in the overall approach to pain and anxiety in intensive care units. Trial registration NCT, NCT03956264. Registered 20 May 2019, https://clinicaltrials.gov/ct2/show/NCT03956264.
参考来源
- Laghlam D, Naudin C, Coroyer L, et al. Virtual reality vs. Kalinox® for management of pain in intensive care unit after cardiac surgery: a randomized study. Ann Intensive Care. 2021. PMID: 33983498. doi:10.1186/s13613-021-00866-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。